home All News open_in_new Full Article

Chinese biotech Scizeng’s global licensing deal to yield up to US$1.44 billion

A Chinese biopharmaceutical firm has sealed a global licensing deal valued at up to US$1.44 billion, the second in a week, as a wave of cross-border tie-ups shows no sign of abating despite headwinds from the US Biosecure Act. Shanghai Scizeng Medical Technology, a unit of Changchun High-Tech Industry, has agreed to grant US-based Yarrow Bioscience exclusive global rights to develop, manufacture and commercialise GenSci098, an injectable therapy for thyroid eye disease and Graves’ disease, both...


today 3 d. ago attach_file Economics

attach_file Politics
attach_file Science
attach_file Science
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Events
attach_file Events
attach_file Events
attach_file Events
attach_file Events
attach_file Events
attach_file Events
attach_file Events
attach_file Politics
attach_file Technology
attach_file Politics
attach_file Politics
attach_file Events


ID: 3676150950
Add Watch Country

arrow_drop_down